We stress again that the novel key contribution of this work is the identification of a gene module that simultaneously correlates with a poor clinical outcome in endocrine-treated ER+ breast cancer and with sensitivity to PI3K/AKT/mTOR inhibitors. This evidence concerns the gene PIK3CA and breast carcinoma.